- Home
- CELC vs VEON Comparison
CELC vs VEON Comparison
Compare CELC & VEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | VEON |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CELC | VEON |
|---|---|---|
| Price | $110.32 | $54.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $100.13 | $73.25 |
| AVG Volume (30 Days) | ★ 629.3K | 68.7K |
| Earning Date | 11-12-2025 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 8.91 |
| Revenue | N/A | ★ $4,226,000,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | ★ N/A | $6.07 |
| Revenue Growth | N/A | ★ 6.74 |
| 52 Week Low | $7.58 | $34.55 |
| 52 Week High | $116.44 | $64.00 |
Technical Indicators
Market Signals| Indicator | CELC | VEON |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 58.15 |
| Support Level | $103.00 | $53.19 |
| Resistance Level | $112.69 | $56.50 |
| Average True Range (ATR) | 6.44 | 1.45 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 70.07 | 57.20 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About VEON VEON Ltd. ADS
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.